Skip to main content
OpenTrials
Completed

NCT Number: NCT00914329

Gelsemium Sempervirens in Anticipatory Anxiety

To evaluate the effectiveness of Gelsemium sempervirens 5CH et 15CH on anticipatory provoked anxiety, in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Clinical Research Center

Grenoble, 38043, France

About this study

State-anxiety can appear during banal events without objective harrowing factors. It is preponderant in particular situations as exams and competitive examination for example, and may be responsible of failures, notably at school. Particularly, a form of anxiety said anticipatory (largely named nerves) is focused on a coming performance. This anticipative anxiety, maximal before the beginning of the test, disappears during this test to let place to relief. Even if phenomenon of habituation exists, it can be responsible of social and professional failures.

Numerous therapeutics exists to fight against anxiety, non medicinal first but the resort to drugs are sometime necessary. The reference is the class of benzodiazepines. Many patients try non conventional medicines, like homeopathy.

Gelsemium sempervirens would be active on sensible et emotional persons, reducing anxiety in some situations. A large used of Gelsemium sempervirens is the case of a situation of provoked stress in particular exam. That is the reason why the drug is particularly intended to a population of young adults who don't want to use " traditional " tranquillizing. But this drug, largely used, has never showed his effectiveness on provoked anxiety, in biomedical research. That is why we proposed in this study to compare the effectiveness of Gelsemium sempervirens 5CH, Gelsemium sempervirens 15CH and placebo, in a situation of provoked anxiety in young adult healthy volunteers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Man or woman,
  • age between 18 et 40 ans,
  • affiliated to a regime of social security or equivalent

Exclusion criteria

  • Medical history of psychiatric disease relevant of psychoses,
  • Medical history of hospitalisation in psychiatric environment,
  • psychotropic substance of the class of antidepressants, antipsychotics and normothymics), in the year before inclusion,
  • Taking, even punctual of psychotropics substances of the class of benzodiazepines and related, in the month before inclusion,
  • Taking, even punctual of psychotropics substances of the class of anxiolytics non benzodiazepines, in the month before inclusion: meprobamate, hydroxyzine, buspirone, captodiamine, pregabalin, etifoxine,
  • Taking, even punctual of substances of the class of the sedatives divers, in the month before inclusion: phytotherapy, homeopathy, sedatives with brome, mineral elements,
  • Taking, even punctual of substances of the class of antihistamine with hypnotic aim, in the month before inclusion,
  • Taking, even punctual of propanolol in the month before inclusion
  • Known Addiction,
  • Handicap incompatible with the Stress Test : blindness, partially sighted, daltonism, dementia, language troubles,
  • Pregnancy, parturient and nursing woman,
  • Person private of freedom by judicial or administrative decision, person under measure of legal protection,
  • allergy to one of the constituents

Treatment and study plan

Gelsemium Sempervirens

Drug

5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

Placebo

Drug

placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

Primary outcomes

  1. Anxiety level evaluated by the STAI-E, in absolute value and et difference with basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)

    Time frame: day 0

Secondary outcomes

  1. anxiety level measured by the visual analogic scale of anxiety, in absolute value and difference with the basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)

    Time frame: day -7, day -5 and day 0

  2. anxiety level measured by the scale of anxiety state in competition (EEAC), in absolute value and difference with the basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)

    Time frame: day 0

  3. Continue measure of arterial pressure, heart rate, respiratory rate, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)

    Time frame: day 0

  4. anxiety measured by STAI-T

    Time frame: day -7 and day -5

  5. score of stress-test

    Time frame: day 0

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Collaborators

  • BOIRON

Registry information

Official study title

Randomized Controlled Study Versus Placebo Evaluating Effectiveness of Gelsemium Sempervirens (5CH et 15CH) on Provoked Anticipatory Anxiety, in Healthy Volunteers

Acronym: ANXIHOMEV

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jun 5, 2009
Registry last updated
Jun 3, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.